Premium
Non‐A Non‐B Hepatitis and the Safety of Intravenous Immune Globulin, pH 4.2: A Retrospective Survey:
Author(s) -
Rousell Ralph H.,
Good Robert A.,
Pirofsky Bernard,
Schiff Richard I.
Publication year - 1988
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1988.tb01605.x
Subject(s) - medicine , hepatitis , alanine transaminase , globulin , transaminase , antibody , gastroenterology , immune system , gamma globulin , immunology , pharmacology , chemistry , enzyme , biochemistry
. Evidence for transmission of non‐A non‐B hepatitis (NANB) was sought in 41 patients with primary immune deficiency who were receiving human intravenous immune globulin (IGIV) over periods ranging from 6 to 15 months at a monthly dosage of 400 mg/kg body weight. One lot of a reduced and alkylated IGIV and three lots of a nonmodified preparation stabilized at pH 4.2 were used. No evidence of NANB was found, although transient elevations in serum glutamic pyruvic transaminase (alanine aminotransferase) were found in 6 of the patients. The possible causes of the elevated levels in these 6 patients are discussed.